Macquarie Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

Macquarie Group’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-539	Closed	-$35K	–	2170
2022 Q3	$35K	Sell	539 -744	-58%	-$15.1K	﹤0.01%	2044
2022 Q2	$18K	Hold	1,283	–	–	﹤0.01%	2343
2022 Q1	$25	Hold	1,283	–	–	﹤0.01%	2338
2021 Q4	$21K	Hold	1,283	–	–	﹤0.01%	2388
2021 Q3	$36K	Hold	1,283	–	–	﹤0.01%	2326
2021 Q2	$38K	Hold	1,283	–	–	﹤0.01%	2220
2021 Q1	$36K	Sell	1,283 -353	-22%	-$9.76K	﹤0.01%	2150
2020 Q4	$46K	Hold	1,636	–	–	﹤0.01%	2058
2020 Q3	$41K	Hold	1,636	–	–	﹤0.01%	2004
2020 Q2	$40K	Buy	+1,636	New	+$32.3K	﹤0.01%	1985
2014 Q4	–	Sell	-6,000	Closed	-$116K	–	1627
2014 Q3	$116K	Hold	6,000	–	–	﹤0.01%	1445
2014 Q2	$204K	Buy	6,000 +749	+14%	+$23.5K	﹤0.01%	1441
2014 Q1	$165K	Buy	+5,251	New	+$164K	﹤0.01%	1437

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Macquarie Group's RVNC Position: Q4 2022 in Review

Macquarie Group sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2022, closing a stake of 539 shares — an estimated $35K sold.

Macquarie Group first reported a position in RVNC in Q1 2014 and held it in 13 quarters. The position peaked at $204K in Q2 2014. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2022.

Macquarie Group reported no remaining Revance Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Macquarie Group sold 539 Revance Therapeutics, Inc. shares in Q4 2022, an estimated $35K.
Macquarie Group first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 13 quarters.
Macquarie Group's Revance Therapeutics, Inc. position peaked at $204K in Q2 2014.
193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2022.

Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.